The genomic landscape of breast cancer and its interaction with host immunity

被引：200

作者：

Luen, Stephen ^{[1
]}

Virassamy, Balaji ^{[1
]}

Savas, Peter ^{[1
]}

Salgado, Roberto ^{[2
]}

Loi, Sherene ^{[1
]}

机构：

[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Inst Jules Bordet, Brussels, Belgium

来源：

BREAST | 2016年 / 29卷

关键词：

Breast cancer; Immunity; Genomics; Immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; EXOME ANALYSIS REVEALS; MUTATIONAL PROCESSES; ANTICANCER CHEMOTHERAPY; RECEPTOR POLYMORPHISMS; PROGNOSTIC VALUE; PREDICTIVE-VALUE; DENDRITIC CELLS; T-CELLS; TRASTUZUMAB;

D O I：

10.1016/j.breast.2016.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular profiling of thousands of primary breast cancers has uncovered remarkable genomic diversity between breast cancer subtypes, and even within subtypes. Only a few driver genes are recurrently altered at high frequency highlighting great challenges for precision medicine. Considerable evidence also confirms the role, of host immunosurveillance in influencing response to therapy and prognosis in HER2+ and triple negative breast cancer. The role of immunosurveillance in ER + disease remains unclear. Advances in both these fields have lead to intensified interest in the interaction between genomic landscapes and host anti-tumour immune responses in breast cancer. In this review, we discuss the potential genomic determinants of host anti-tumour immunity - mutational load, driver alterations, mutational processes and neoantigens - and their relationship with immunity in breast cancer. Significant differences exist in both the genomic and immune characteristics amongst breast cancer subtypes. While ER + disease appears to be less immunogenic than HER2+ and triple negative breast cancer, it displays the greatest degree of heterogeneity. Mutational and neoantigen load appears to incompletely explains immune responses in breast cancer. Driver alterations do not appear to increase immunogenicity. Instead, they could contribute to immune-evasion or an immunosuppressive microenvironment, and therefore represent potential therapeutic targets. Finally, we also discuss the tailoring of immunotherapeutic strategies by genomic alterations, with possible multimodal combination approaches to maximise clinical benefits. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：241 / 250

页数：10

共 110 条

[1] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].

Albert, ML ;

Sauter, B ;

Bhardwaj, N .

NATURE, 1998, 392 (6671) :86-89

[4] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[5] Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].

Ali, H. R. ;

Provenzano, E. ;

Dawson, S-J ;

Blows, F. M. ;

Liu, B. ;

Shah, M. ;

Earl, H. M. ;

Poole, C. J. ;

Hiller, L. ;

Dunn, J. A. ;

Bowden, S. J. ;

Twelves, C. ;

Bartlett, J. M. S. ;

Mahmoud, S. M. A. ;

Rakha, E. ;

Ellis, I. O. ;

Liu, S. ;

Gao, D. ;

Nielsen, T. O. ;

Pharoah, P. D. P. ;

Caldas, C. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543

[6] Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer [J].

Amir, Eitan ;

Miller, Naomi ;

Geddie, William ;

Freedman, Orit ;

Kassam, Farrah ;

Simmons, Christine ;

Oldfield, Maria ;

Dranitsaris, George ;

Tomlinson, George ;

Laupacis, Andreas ;

Tannock, Ian F. ;

Clemons, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :587-592

[7] Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) [J].

Andre, Fabrice ;

Bachelot, Thomas ;

Commo, Frederic ;

Campone, Mario ;

Arnedos, Monica ;

Dieras, Veronique ;

Lacroix-Triki, Magali ;

Lacroix, Ludovic ;

Cohen, Pascale ;

Gentien, David ;

Adelaide, Jose ;

Dalenc, Florence ;

Goncalves, Anthony ;

Levy, Christelle ;

Ferrero, Jean-Marc ;

Bonneterre, Jacques ;

Lefeuvre, Claudia ;

Jimenez, Marta ;

Filleron, Thomas ;

Bonnefoi, Herve .

LANCET ONCOLOGY, 2014, 15 (03) :267-274

[8] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[9] Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer [J].

Arnedos, M. ;

Drury, S. ;

Afentakis, M. ;

A'Hern, R. ;

Hills, M. ;

Salter, J. ;

Smith, I. E. ;

Reis-Filho, J. S. ;

Dowsett, M. .

ANNALS OF ONCOLOGY, 2014, 25 (03) :605-610

[10] Precision medicine for metastatic breast cancer-limitations and solutions [J].

Arnedos, Monica ;

Vicier, Cecile ;

Loi, Sherene ;

Lefebvre, Celine ;

Michiels, Stefan ;

Bonnefoi, Herve ;

Andre, Fabrice .

NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (12) :693-704

← 1 2 3 4 5 6 7 8 9 10 →